A number of other research firms have also issued reports on DVA. William Blair reissued a buy rating on shares of Davita in a research note on Thursday, June 20th. Deutsche Bank reduced their target price on shares of Davita from $68.00 to $66.00 and set a buy rating for the company in a research note on Thursday, May 9th. TheStreet raised shares of Davita from a c+ rating to a b- rating in a research note on Wednesday, July 24th. Zacks Investment Research raised shares of Davita from a sell rating to a hold rating in a research note on Friday, May 10th. Finally, Robert W. Baird lowered shares of Davita from an outperform rating to a neutral rating and reduced their target price for the company from $70.00 to $65.00 in a research note on Friday, July 26th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. Davita presently has a consensus rating of Hold and an average target price of $67.21.
NYSE DVA opened at $54.70 on Tuesday. Davita has a one year low of $43.40 and a one year high of $79.11. The company has a 50-day simple moving average of $58.05 and a 200-day simple moving average of $54.41. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.10 and a current ratio of 1.12. The firm has a market capitalization of $8.96 billion, a PE ratio of 15.32, a price-to-earnings-growth ratio of 0.54 and a beta of 1.59.
Institutional investors have recently bought and sold shares of the business. Rehmann Capital Advisory Group raised its position in shares of Davita by 467.3% during the 1st quarter. Rehmann Capital Advisory Group now owns 556 shares of the company’s stock worth $30,000 after buying an additional 458 shares in the last quarter. Clearbridge Investments LLC raised its position in shares of Davita by 63.5% during the 1st quarter. Clearbridge Investments LLC now owns 798 shares of the company’s stock worth $43,000 after buying an additional 310 shares in the last quarter. CSat Investment Advisory L.P. raised its position in shares of Davita by 54.0% during the 1st quarter. CSat Investment Advisory L.P. now owns 895 shares of the company’s stock worth $49,000 after buying an additional 314 shares in the last quarter. Quadrant Capital Group LLC raised its position in shares of Davita by 2,481.1% during the 1st quarter. Quadrant Capital Group LLC now owns 955 shares of the company’s stock worth $50,000 after buying an additional 918 shares in the last quarter. Finally, Employers Holdings Inc. bought a new stake in shares of Davita during the 2nd quarter worth about $56,000. 88.90% of the stock is owned by hedge funds and other institutional investors.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: Economic Bubble
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.